To explore the potential usefulness of serum microRNA (miR-122) as non-invasive diagnostic marker for hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC). Methods: The study has been conducted on 100 participants and were divided into 4 equal groups: Group I; Twenty five normal, healthy individuals' age and gender-matched healthy volunteers (control group). Group II; Twenty five chronic HCV patients without cirrhosis. Group III; Twenty five HCV related cirrhosis without HCC. Group IV; Twenty five HCV-related HCC (proved radiologically by abdominal ultrasonography (US) & Triphasic abdominal computed tomography (CT). All participants underwent full clinical assessment and laboratory investigations in addition to the evaluation of the level of serum miR-122 by RT-PCR. Results: microRNA-122 displayed significant fold increase in expression level in chronic hepatitis group (9.85), and less significant fold increase in cirrhosis group (3.73) and significant fold increase in expression level in HCC group (7.46). Comparing serum miR-122 expression level between different studied groups displayed that, No significant fold change in miR-122 expression was found between different groups and that miRNA122 had no significant up-regulation in HCC patients in comparison to non-HCC patients (Hepatitis and Cirrhosis); (P value = 0.682). Specificity & sensitivity was 94% & 16% respectively, with AUROC (0.529). Conclusion: miR-122 could not be used as a biomarker for early detection of HCC in HCV related cirrhosis.
Introduction
HCC is the most common primary liver cancer and the fifth most common cancer worldwide and considered the second leading cause of cancer-related mortality in the world and accounts for 7% of all cancers 1 . In Egypt, there is a remarkable increase in the annual proportion of HCC among chronic liver disease patients from 4% to 7.2% 2 . Chronic HCV accounted for 94% of HCC cases in Egypt in 2010, with 6000-7000 deaths/year due to HCC 3 . Early HCC stage is asymptomatic and clinical manifestations are obvious only in the advanced stage, resulting in an undesirable curative effect and very bad prognos 4 . Early diagnosis of HCC by good surveillance represents the best requirement for an effective treatment to extend the lifetime of HCC patients 5, 6 . Alpha fetoprotein (AFP) has long been used for the diagnosis of HCC. It has also been part of surveillance algorithms. However, the AFP is insufficiently sensitive or specific for use as a surveillance assay 7 . Guidelines published by EASL, 2012 & AASLD, 2010 rejected AFP whether for the surveillance or the diagnosis of HCC. So, the need for other methods that would be minimallyinvasive, simple and reliable for the early detection of HCC is mandatory. MicroRNAs (miRNAs) are endogenous, evolutionally conserved, non-coding RNAs that have been identified as posttranscriptional regulators of gene expression. MiRNAs are known to play various roles in the carcinogenesis process, including metastasis, tumor invasion, cell proliferation, cell cycle, and apoptosis 8 . In HCC, several tumor-suppressing and oncogenic miRNAs may have potential application in early diagnosis
MicroRNA 122 as adiagnostic biomarker for hepatitis C-related hepatocellular carcinoma
and prediction of prognosis 9,10 . MiR-122 is the most abundant hepatic miRNA, and it is involved in the proliferation and differentiation of hepatocytes
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. MiR-122 is frequently reported to be down regulated in HCC; however, some investigators have reported up regulation of this miRNA, depending on the etiology of HCC. Serum levels of miR-122 were reported to be higher in patients with HCC or hepatitis than in the healthy controls 12 . The aim of our study is to evaluate the possibility of using serum miR-122 for early detection of HCC.
Materials and Methods
This cross sectional observational study was performed on patients selected from the outpatient hepatology clinics and HCC early detection clinic, in Egyptian Liver Hospital (ELH) and
Specialized Medical Hospital (SMH), Mansoura University, Egypt, from April 2016 to April 2017. The study has been conducted on 100 participants and was divided into 4 equal groups: Group I; Twenty five normal healthy individuals age and gender-matched healthy volunteers (control group). Group II; Twenty five chronic HCV patients without cirrhosis. Group III; Twenty five HCV related cirrhosis without HCC. Group IV; Twenty five HCVrelated HCC (proved radiologically by abdominal US & Triphasic abdominal CT). All patients were enrolled in our study after signing an informed written consent. Approval of the study protocol by the medical ethics research committee, Faculty of Medicine, Mansoura University was obtained. Exclusion criteria included: Previous treatment of HCC (surgical, interventional or medical), presence of other malignancies (e.g. cholangiocarcinoma, gastric, colorectal cancer), patients with HCC on top of other causes rather than HCV, and patients on direct acting antiviral therapy for chronic HCV. All participants were subjected to full medical history, complete clinical examination, and full basal laboratory and radiological investigations with collecting samples for serum miR-122 and serum AFP. Serum sample collection: Five milliliters of venous blood was obtained and the serum fraction was extracted and stored at -80 °C until used. RNA extraction: For the real-time PCR, RNA was extracted from serum using QIAzolLysis reagent according to the manufacturer's instructions. The RNA purity was assessed by the RNA concentration and quantified by NanoDrop ND-1000 (Nanodrop, United States). Reverse tra-nscription using miScript II RT Kit: Only 5 x miScriptHiSpec Buffer had been used preparation of cDNA for real-time PCR with miScriptmiRNA PCR Arrays. Single-stranded cDNAs were generated using the RT kit according to the manufacturer's directions (miSCr-iptmiRNA PCR system, miRneasy mini kit for miRNAextraction, miScript RT Ⅱ formiRNA reverse transcription, miSCript Primer Assay and miScript SYBR Green PCR Kit for PCR amplification. RNA quantification: PCR quantification experiments were performed with PCR (Applied Biosystems; Foster City, CA) using the SYBR Green PCR Master Mix according to the manufacturer's protocol. The primers for miR-122 and housekeeping gene were supplied by Qiagene, Germany.
Statistical analysis
Patients were categorized into 4 groups; normal, Chronic hepatitis, Cirrhosis and HCC. Further comparisons were performed between HCC group and Non-HCC (chronic hepatitis and cirrhosis). Quantitative variables were expressed by mean ± SD or expressed by median and inter quartile range (IQR) for non-parametric data. They were compared by t-students t-test or ANOVA test when appropriate. Qualitative variables were compared by ÷2 or Fischer's exact test when appropriate. Receiver operator characteristic (ROC) curves were constructed to assess the value of miRNA 122 in diagnosing HCC and to assess area under the curve (AU ROC). Spearmen and Pearson correlations were done for correlating quantitative variables. In all tests, P value was considered significant if equal or less than 0.05.
Results
The clinico-demographic &laboratory data of the studied participants are shown in tabs. (1 & 2) . Table (1) shows that there was no significant statistical difference between cirrhosis & HCC groups regarding special habits & presence of hypertension. There was a significant difference between the diseased groups regarding age (P <0.001). Regarding gender difference; males were predominant in HCV related liver disease patients. Rural residency and presence of diabetes mellitus (DM) were statistically significant higher in HCC patients, and most cases of HCC were clinically asymptomatic discovered during their routine follow up. (3) shows that miR-122 displayed significant fold increase in expression level in chronic hepatitis group (9.85), and less significant fold increase in cirrhosis group (3.73 ) and significant fold increase in expression level in HCC group (7.46 ). Comparing serum miR-122 expression level between different studied groups displayed that, No significant fold change in miR-122 expression was found between either (HCC vs Hepatitis groups) or (HCC vs cirrhosis groups) nor (Hepatitis vs cirrhosis). respectively), and most cases were staged 0, A and B (12%, 36%, 24% respectively) according to BCLC scoring system, a result that was in agreement with manu previous studies 13,16,26 . This could be explained by the fact that, most of them were recruited while being assessed for the possibility of interventional treatment. Another possible explanation for rather good liver condition seen in HCC series could be attributed to the implementing surveillance programs, allowing detecting tumors at an early stage in well compensated patients, but disagreeing with the result of Ziada et al, where 91.3% of HCC cases were Child B or C 27 . In HCC group the incidence of single lesion was more than multiple lesions (72% and 28% respectively), and 56.5% of HCC cases were found as small sized HCC. This result was hand in hand with other studies 16,26 demonstrated that, most of patients have single focal lesion. Also, this also may be attri-buted to effective surveillance strategies for early diagnosis of HCC. In this study, there were significant differences in serum AFP level between different groups. It was significantly higher in HCC group (23.09 ng/ ml). These results are in agreement with results of other studies 15,25,28 . Also, consistent with Montaser et al, who stated highly significant increase in the serum AFP in the HCC cases (31.67 ng/ml) 29 . Our study proved that miR-122 could not be used as a biomarker for early detection of HCC in HCV related cirrhosis, as it was found that miR-122 displayed significant fold increase in expression level in chronic hepatitis group 9 , and less significant fold increase in cirrhosis group 3 , and significant fold increase in expression level in HCC group 7 . Comparing serum miR-122 expression level between different studied groups displayed that; No significant change in miR-122 expression was found between either (HCC vs hepatitis groups) or (HCC vs cirrhosis groups) nor (hepatitis vs cirrhosis) and that miR 122 had non significant upregulation in HCC patients in comparison to non-HCC patients (hepatitis and cirrhosis), with specificity and sensitivity (94% & 16% respectively). The explanation is that miR-122 is a liver specific miRNA, and its serum level is increased with hepatocyte injury induced by HCV. Our result was hand in hand with Ghoneimet et al, who stated that the expression level of serum miR-122 displayed a significant fold increase in serum 30 . In our study, miR-122 in the HCV group and cirrhosis as compared with the control group, but patients with HCC showed a non significantly higher expression level of miR-122 as compared with controls. Our results also were in agreement with El-Garem et al, who found that, miR-122 was up regulated in chronic hepatitis and non significant upregulation in HCC patients in comparison to non-HCC patients (chronic hepatitis and cirrhosis), but show fold decrease in cirrhosis in contrary to our results 13 . Our results match also with Miquelestorena et al, who showed that higher levels of miR-122 were found in non HCC HCV positive cases compared to HCV related HCC and control groups 31 . Our results also similar to that of Balkan et al, who found that comparison of serum miR-122 levels between patients with HCC and control group diagnosed with non alcoholic fatty liver disease (NAFLD) showed no statistically significant difference 32 . Our results also in agreement with Motawi et al, who found that, the serum levels of miR-122 was significantly elevated in HCV patients, but not in liver cancer patients, compared with controls and concluded that serum miR-122 is elevated in Egyptian patients with chronic HCV, and these miRNAs have a strong potential to serve as novel biomarkers for liver injury but not specifically for liver cancer 33 . EL-Abd et al 34 in agreement with our study showed that, no significant difference was observed for miR-122 between the HCV and HCC groups. Our results cope also with Ezzat et al 35 who showed that expression level of miR-122 was significantly higher in both HCV and cirrhotic groups as compared to control group, patients with HCC showed non significant higher expression level of miR-122 as compared to cases with cirrhosis alone. Also our results cope with Qi et al 36 who reported that serum miR-122 was significantly higher in HCC patients than healthy controls but not specifically for detection of HCC in chronic HBV infection patients. Also in agreement with Xu et al 12 found that the levels of miR-122 was significantly higher in patients with HCC than healthy controls and also elevated in patients with chronic hepatitis suggesting that the elevated serum miR-122 may reflect liver injury but not tumor itself similar to our results. Zekri et al 37 found that, miR-122 was significantly up regulated in HCC, and provided high diagnostic accuracy in contrast to our results, but this may be due to using combinations of different panels of miRNAs in addition to miR-122. Also, Demerdash et al 38 proved that plasma miR-122 was significantly higher in chronic HCV and HCC in comparison to healthy controls, but in contrary to our result there was more significant increase in HCC compared to hepatitis group. Against our results, El-Shennawy et al 39 found that, the highest expression of plasma level of miR-122 was in HCC in comparison to cirrhosis and ROC curve analysis yielded 73% sensitivity and 96 % specificity, this may be due to their limited small sample size. In contrast to our result, Wang et al 40 found that miR-122 expression in liver was significantly down-regulated. But this may be explained by study was conducted on HBV cases in contrast to our HCV patients. Also in contrast to our results, Huang et al 41 performed a systematic review and meta-analysis and revealed that miR-21 and miR-122 individually distinguished patients with HCC from healthy controls, with an AUC of 0.77 for miR-122. In contrast to our results, significant down regulation of miR-122 in HCC compared to normal liver tissue was reported by others 42-44 , but this may be attributed to mixed etiologies of HCC. Also, Ladeiro et al 45 have established significant down expression of miR-122 in 28 HCC liver tissues (mixed etiologies). similarly a significant down regulation in miR-122 in 19 HBV related HCC liver tissue reported by Connolly et al 46 .
Conclusion miR-122 could not be used as a biomarker for early detection of HCC in HCV related cirrhosis, as it showed non-significant upregulation in HCC patients in comparison to non-HCC patients.
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